title: How Precisely Can Prostate Cancer Be Managed?
abstract: Progress has been made in applying genetic information to disease management in the postgenomic era, and precision medicine is emerging in prostate cancer management. The prostate health index, the 4-kallikrein (4K) score, and the PCA3, TMPRSS2- ERG, and Prostarix tests have potential for refining prostate cancer screening in conjunction with traditional prostate-specific antigen testing. The Confirm MDx and PCA3 tests have shown promise in identifying men who need be rebiopsied after a primary negative biopsy. Oncotype DX, Prolaris, the biopsy-based Decipher prostate cancer test, and ProMark may improve predictive risk stratification in addition to the traditional Gleason score and tumor stage. Decipher and Prolaris may predict biochemical recurrence and metastasis after radical prostatectomy and possibly help identify patients who need adjuvant therapy. Androgen receptor splice variant 7 appears effective in guiding the selection of second hormonal manipulation with abiraterone or enzalutamide versus chemotherapy when treating metastatic castration-resistant prostate cancer.
authors.affiliation: Department of Urology, Lahey Hospital and Medical Center, Tufts University School of Medicine, Burlington, MA, USA.
authors.forename: Liyan
authors.identifier: 0000-0003-2258-0176
authors.initials: L
authors.lastname: Zhuang
authors.affiliation: Urology Consultants, Ltd., St. Louis, MO, USA.
authors.forename: Matthew T
authors.identifier: 0000-0002-9793-7902
authors.initials: MT
authors.lastname: Johnson
keywords: Biomarkers; Precision Medicine; Prostatic Neoplasms; Receptors, Androgen